Botulinum toxin type A in the treatment of sialorrhea in patients with Parkinson’s disease

Abstract

Drooling is defined as excess saliva in the mouth that exceeds the margin of the lips. The injection of botulinum toxin type A appears to be the safest as it offers a range of effectiveness up to 3 months. Objectives: To study whether low (75 units) of abobotoxina type in the parotid gland of patients with Parkinson’s disease and drooling, dose is effective without the presence of adverse effects. Methods: cross-sectional study in patients with drooling scale clinical scale for Parkinson disease (SCS-PD), severity and frequency of salivation (DSFS), at the time of study entry and at weeks 1, 2, 4 , 8, 12, 16. Results: 6 patients were included in the study, with a mean age of 67.3 years, 11.8 years on average for developing Parkinson’s four years of suffering drooling. Analysis of decreasing an overall score for SCS-PD from baseline to week 12, presents statistical significance (p = 0.0030) thus corroborating the beneficial effect of the toxin for at least 3 months. Conclusions: a dose of 75 units abobotoxina type A appears to be suitable for symptom control without creating undesirable side effects start from the first week of the application keeping up to 3 months after starting treatment.